[go: up one dir, main page]

Mendrick et al., 1991 - Google Patents

Antigen processing and presentation by glomerular visceral epithelium in vitro

Mendrick et al., 1991

View PDF
Document ID
17666451195611929198
Author
Mendrick D
Kelly D
Rennke H
Publication year
Publication venue
Kidney international

External Links

Snippet

Antigen processing and presentation by glomerular visceral epithelium in vitro. Although macrophages are considered the prototype of antigen presenting cells (APC), recent studies have emphasized the potential role of several parenchymal and mesenchymal cells in this …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
US11000566B2 (en) Compositions and methods for modulating the immune system
Koyama et al. A glomerular permeability factor produced by human T cell hybridomas
Taylor et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
Chapman et al. Endothelial activation in monosodium urate monohydrate crystal‐induced inflammation. In vitro and in vivo studies on the roles of tumor necrosis factor α and interleukin‐1
Cooper et al. Acceleration of onset of collagen‐induced arthritis by intra‐articular injection of tumour necrosis factor or transforming growth factor‐beta
Hanspal et al. The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact
Unanue et al. LIGAND-INDUCED MOVEMENT OF LYMPHOCYTE MEMBRANE MACROMOLECULES: III. Relationship Between the Formation and Fate of Anti-Ig-Surface Ig Complexes and Cell Metabolism
Mendrick et al. Antigen processing and presentation by glomerular visceral epithelium in vitro
Buyon et al. Neonatal lupus: review of proposed pathogenesis and clinical data from the US-based Research Registry for Neonatal Lupus
Schulze et al. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat
JPH03201995A (en) Monoclonal antibody against active endothelial cell, medicine and treating method using the same monoclonal antibody and its antigen and diagnostic method using the same monoclonal antibody
US5403919A (en) Method to control leukocyte extravasation
Buzás et al. A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice.
KR100371000B1 (en) Rheumatism
van Es Pathogenesis of IgA nephropathy
Billings et al. Expression of Β Ig-H3 by Human Bronchial Smooth Muscle Cells: Localization to the Extracellular Matrix and Nucleus
Neufing et al. Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells
Fudenberg et al. Agammaglobulinemia: Some current concepts
JPS6236325A (en) Treatment by suppressor for self immune disease like rheumatic arthritis
JPH02196A (en) Method for controlling extravasation of leukocyte
AU665764B2 (en) Methods and compositions for the prevention, diagnosis, and treatment of inflammatory serosal disease and related conditions
US5869048A (en) Method of treating ulcerative colitis with a monoclonal antibody
Davenport et al. Brain‐reactive autoantibodies in BB/d rats do not recognize glutamic acid decarboxylase
JP3055006B2 (en) Rheumatic treatment
US20050008639A1 (en) Methods of modulating homing of T cell by interruption of chemokine/chemokine receptor signaling